Bupropion Alone or Combined With Nicotine Gum

NCT ID: NCT01621022

Last Updated: 2016-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

608 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-01-31

Study Completion Date

2002-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Focus of this study was to determine if bupropion was more effective for smoking cessation when used alone or combined with nicotine gum.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Dependence

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

smoking cessation tobacco dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active bupropion-Active gum

150 mg bupropion twice daily + 4 mg nicotine gum as needed (up to 12 pcs/day)

Group Type ACTIVE_COMPARATOR

bupropion + nicotine gum

Intervention Type DRUG

150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)

Active bupropion-Placebo gum

150mg bupropion twice daily + placebo gum as needed (up to 12 pcs/day)

Group Type ACTIVE_COMPARATOR

Active bupropion-Placebo gum

Intervention Type DRUG

150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)

Placebo medication-Placebo gum

Placebo bupropion, twice daily, plus placebo gum as needed (up to 12 pcs/day)

Group Type ACTIVE_COMPARATOR

Placebo bupropion-Placebo gum

Intervention Type DRUG

Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bupropion + nicotine gum

150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)

Intervention Type DRUG

Active bupropion-Placebo gum

150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)

Intervention Type DRUG

Placebo bupropion-Placebo gum

Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Smoke 10 or more cigarettes per day
* Motivated to quit
* No physical or mental health issues that would prevent participation
* Not pregnant or willing to prevent pregnancy during treatment

Exclusion Criteria

* Carbon monoxide (CO) breath test score below 10 parts per million (ppm)
* Center for Epidemiologic Studies Depression Scale (CES-D) score greater than 16
* Heavy alcohol use
* History of eating disorder
* Suicidality
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

University of Wisconsin, Madison

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UW Center for Tobacco Research and Intervention

Madison, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, Baker TB. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res. 2007 Sep;9(9):947-54. doi: 10.1080/14622200701540820.

Reference Type RESULT
PMID: 17763111 (View on PubMed)

Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023 May 24;5(5):CD000031. doi: 10.1002/14651858.CD000031.pub6.

Reference Type DERIVED
PMID: 37230961 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB S-01-07

Identifier Type: -

Identifier Source: org_study_id